Literature DB >> 29479282

Update on invasive meningococcal vaccination for Canadian children and youth.

Joan L Robinson1.   

Abstract

Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.

Entities:  

Keywords:  IMD; Meningitis; Sepsis; Vaccine

Year:  2018        PMID: 29479282      PMCID: PMC5814812          DOI: 10.1093/pch/pxx162

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  12 in total

1.  Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.

Authors:  Miguel Tregnaghi; Pio Lopez; Daniel Stamboulian; Gabriela Graña; Tatjana Odrljin; Lisa Bedell; Peter M Dull
Journal:  Int J Infect Dis       Date:  2014-06-26       Impact factor: 3.623

2.  Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies.

Authors:  L Miriam Pina; Ehab Bassily; Agnes Machmer; Victor Hou; Albert Reinhardt
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

3.  Meningococcal vaccines in Canada: An update.

Authors:  Mi Salvadori; R Bortolussi
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

4.  Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

Authors:  Ameneh Khatami; Matthew D Snape; Elizabeth Davis; Helen Layton; Tessa John; Ly-Mee Yu; Peter M Dull; Christopher J Gill; Tatjana Odrjlin; Simon Dobson; Scott A Halperin; Joanne M Langley; Shelly A McNeil; Andrew J Pollard
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

5.  Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

Authors:  Timo Vesikari; Roman Prymula; Elizabeth Merrall; Igor Kohl; Daniela Toneatto; Peter M Dull
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

6.  A new meningococcal conjugate vaccine: What should physicians know and do?

Authors:  R Bortolussi; M Salvadori
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

7.  Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

Authors:  Fiona McQuaid; Matthew D Snape; Tessa M John; Sarah Kelly; Hannah Robinson; Ly-Mee Yu; Daniela Toneatto; Diego D'Agostino; Peter M Dull; Andrew J Pollard
Journal:  CMAJ       Date:  2015-03-23       Impact factor: 8.262

8.  Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study.

Authors:  Manish Sadarangani; David W Scheifele; Scott A Halperin; Wendy Vaudry; Nicole Le Saux; Raymond Tsang; Julie A Bettinger
Journal:  Clin Infect Dis       Date:  2015-01-20       Impact factor: 9.079

9.  One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.

Authors:  Nicola P Klein; Yaela Baine; Veronique Bianco; Pascal R Lestrate; Aftab Naz; Mark Blatter; Leonard R Friedland; Jacqueline M Miller
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

10.  The disease burden of invasive meningococcal serogroup B disease in Canada.

Authors:  Julie A Bettinger; David W Scheifele; Nicole Le Saux; Scott A Halperin; Wendy Vaudry; Raymond Tsang
Journal:  Pediatr Infect Dis J       Date:  2013-01       Impact factor: 2.129

View more
  1 in total

1.  Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children.

Authors:  Joan L Robinson; Sergio Fanella; Alison Lopez; Craig Frankel; Jane McDonald; Mohammad Alghounaim; Robert Slinger; Jennifer Bowes; Sarah Khan; Jeannette L Comeau; Kirk Leifso; John Gunawan; Michelle Barton
Journal:  Can Commun Dis Rep       Date:  2020-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.